AKT1 is altered in 2.02% of liposarcoma patients [2].

AKT1 is an inclusion eligibility criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

AKT2 is altered in 2.47% of liposarcoma patients [2].

AKT2 is an inclusion eligibility criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

AKT3 is altered in 0.46% of liposarcoma patients [2].

AKT3 is an inclusion eligibility criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CCND1 is altered in 2.03% of liposarcoma patients [2].

CCND1 is an inclusion eligibility criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and liposarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CDK4 is altered in 66.07% of liposarcoma patients [2].

CDK4 is an inclusion eligibility criterion in 2 clinical trials for liposarcoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 status and liposarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [3].

Palbociclib has evidence of efficacy in patients with CDK4 mutation in liposarcoma [3].

CRKL is altered in 1.16% of liposarcoma patients [2].

CRKL is an inclusion eligibility criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

DDIT3 is altered in 9.8% of liposarcoma patients [2].

DDIT3 is an inclusion eligibility criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains DDIT3 status and liposarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 is altered in 0.99% of liposarcoma patients [2].

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and liposarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM2 is altered in 68.75% of liposarcoma patients [2].

MDM2 is an inclusion eligibility criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and liposarcoma as inclusion criteria, 1 is phase 3 (1 open) [3].

MTOR is altered in 1.13% of liposarcoma patients [2].

MTOR is an inclusion eligibility criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MYCN is altered in 0.22% of liposarcoma patients [2].

MYCN is an inclusion eligibility criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PDGFRA is altered in 2.0% of liposarcoma patients [2].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3CA is altered in 5.92% of liposarcoma patients [2].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3CG is altered in 1.18% of liposarcoma patients [2].

PIK3CG is an inclusion eligibility criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R1 is altered in 0.9% of liposarcoma patients [2].

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R2 is altered in 1.6% of liposarcoma patients [2].

PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R2 status and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PTEN is altered in 4.18% of liposarcoma patients [2].

PTEN is an inclusion eligibility criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RICTOR is altered in 2.69% of liposarcoma patients [2].

RICTOR is an inclusion eligibility criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains RICTOR status and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RPTOR is altered in 2.13% of liposarcoma patients [2].

RPTOR is an inclusion eligibility criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TSC1 is altered in 1.34% of liposarcoma patients [2].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TSC2 is altered in 1.99% of liposarcoma patients [2].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].